204 related articles for article (PubMed ID: 31369771)
1. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts.
Nofal A; Marei A; Ibrahim AM; Nofal E; Nabil M
J Am Acad Dermatol; 2020 Jan; 82(1):94-100. PubMed ID: 31369771
[TBL] [Abstract][Full Text] [Related]
2. Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts.
Marei A; Nofal A; Alakad R; Abdel-Hady A
J Cosmet Dermatol; 2020 Mar; 19(3):758-762. PubMed ID: 31328869
[TBL] [Abstract][Full Text] [Related]
3. Intralesional bivalent human papilloma virus vaccine as a treatment for anogenital warts versus topical podophyllin resin 25%: A pilot study.
Nofal E; Emam S; Aldesoky F; Ghonemy S; Adelshafy A
Dermatol Ther; 2022 May; 35(5):e15384. PubMed ID: 35170176
[TBL] [Abstract][Full Text] [Related]
4. Intralesional bivalent and quadrivalent human papillomavirus vaccines didn't significantly enhance the response of multiple anogenital warts when co-administered with intralesional Candida antigen immunotherapy. A randomized controlled trial.
Fawzy M; Nofal E; Abdelkhalek N; Ehab R
Arch Dermatol Res; 2023 Dec; 315(10):2813-2823. PubMed ID: 37573268
[TBL] [Abstract][Full Text] [Related]
5. Intralesional Versus Intramuscular Hepatitis B Virus Vaccine in the Treatment of Multiple Common Warts.
Nofal A; Elaraby A; Elkholy BM
Dermatol Surg; 2022 Nov; 48(11):1178-1184. PubMed ID: 36165681
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach.
Nofal A; Nofal E; Yosef A; Nofal H
Int J Dermatol; 2015 Jun; 54(6):667-71. PubMed ID: 25070525
[TBL] [Abstract][Full Text] [Related]
8. Treatment response and tolerability of intralesional quadrivalent versus bivalent human papillomavirus vaccine for recalcitrant warts: A randomized controlled trial.
Nofal A; Nofal H; Alwirshiffani E; ElGhareeb MI
J Am Acad Dermatol; 2023 Nov; 89(5):1051-1052. PubMed ID: 37422014
[No Abstract] [Full Text] [Related]
9. Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts.
Bar-Ilan E; Bar J; Baniel A; Slodownik D; Artzi O; Samuelov L; Sprecher E; Mashiah J
J Dermatol; 2023 Nov; 50(11):1373-1380. PubMed ID: 37501372
[TBL] [Abstract][Full Text] [Related]
10. Intralesional immunotherapy of plantar warts: report of a new antigen combination.
Gamil H; Elgharib I; Nofal A; Abd-Elaziz T
J Am Acad Dermatol; 2010 Jul; 63(1):40-3. PubMed ID: 20462659
[TBL] [Abstract][Full Text] [Related]
11. Intralesional vitamin D3 versus Candida antigen immunotherapy in the treatment of multiple recalcitrant plantar warts: A comparative case-control study.
Fathy G; Sharara MA; Khafagy AH
Dermatol Ther; 2019 Sep; 32(5):e12997. PubMed ID: 31225688
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recalcitrant warts with Bacillus Calmette-Guérin: a promising new approach.
Nofal A; Yosef A; Salah E
Dermatol Ther; 2013; 26(6):481-5. PubMed ID: 24552412
[TBL] [Abstract][Full Text] [Related]
13. Intralesional immunotherapy for multiple recalcitrant plantar warts: Candida antigen is superior to intralesional purified protein derivative.
Nofal A; Adel L; Fawzy M; Elkholy BM
Dermatol Ther; 2022 Jun; 35(6):e15440. PubMed ID: 35285995
[TBL] [Abstract][Full Text] [Related]
14. Intralesional immunotherapy for pediatric warts: A review.
Fields JR; Saikaly SK; Schoch JJ
Pediatr Dermatol; 2020 Mar; 37(2):265-271. PubMed ID: 31930595
[TBL] [Abstract][Full Text] [Related]
15. The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Non-genital Warts: A Retrospective Study.
Kuan LY; Chua SH; Pan JY; Yew YW; Tan WP
Ann Acad Med Singap; 2020 Oct; 49(10):749-755. PubMed ID: 33283838
[TBL] [Abstract][Full Text] [Related]
16. Intralesional Candida antigen versus intralesional vitamin D3 in the treatment of recalcitrant multiple common warts.
Abdel Razik LH; Obaid ZM; Fouda I
J Cosmet Dermatol; 2021 Oct; 20(10):3341-3346. PubMed ID: 34228877
[TBL] [Abstract][Full Text] [Related]
17. Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy.
Hammad NM; Marei A; El-Didamony G; Mortada Z; Elradi M; Afifi AHM; Kadry HM
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835211
[TBL] [Abstract][Full Text] [Related]
18. Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts.
Fouda I; Mohammed HAK; Mohammed GMY
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810062
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens.
Clifton MM; Johnson SM; Roberson PK; Kincannon J; Horn TD
Pediatr Dermatol; 2003; 20(3):268-71. PubMed ID: 12787281
[TBL] [Abstract][Full Text] [Related]
20. Comment on: "Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts".
Taheri A; Mansoori P
J Am Acad Dermatol; 2020 Mar; 82(3):e101-e102. PubMed ID: 31682862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
